Evidence map›Paper›PMID 30658710›Full record

ArticleMalaria journal2019

Immunoglobulin G subclass and antibody avidity responses in Malian children immunized with Plasmodium falciparum apical membrane antigen 1 vaccine candidate FMP2.1/AS02

Andrea A Berry, Eric R Gottlieb, Bourema Kouriba, Issa Diarra, Mahamadou A Thera, Sheetij Dutta, Drissa Coulibaly, Amed Ouattara, Amadou Niangaly, Abdoulaye K Kone and 11 more

Open access · goldAbstract read
In one paragraph

Article in Malaria journal, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed, 1 pooled it
2.4field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 1 synthesis or guideline pooled it, 14 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Vaccines · 2021
    Review
  4. Article
  5. Article
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

21 authors at 4 institutions in 2 countries.

Andrea A BerryCenter for Vaccine Development and Global Health, University of Maryland School of Medicine, Baltimore, MD, USA. aberry@som.umaryland.edu.ORCID http://orcid.org/0000-0003-3140-3868
Eric R GottliebCenter for Vaccine Development and Global Health, University of Maryland School of Medicine, Baltimore, MD, USA.
Bourema KouribaUniversity of Sciences, Techniques, and Technologies, Bamako, Bamako, Mali.
Issa DiarraUniversity of Sciences, Techniques, and Technologies, Bamako, Bamako, Mali.
Mahamadou A TheraUniversity of Sciences, Techniques, and Technologies, Bamako, Bamako, Mali.
Sheetij DuttaWalter Reed Army Institute of Research, Silver Spring, MD, USA.
Drissa CoulibalyUniversity of Sciences, Techniques, and Technologies, Bamako, Bamako, Mali.
Amed OuattaraCenter for Vaccine Development and Global Health, University of Maryland School of Medicine, Baltimore, MD, USA.
Amadou NiangalyUniversity of Sciences, Techniques, and Technologies, Bamako, Bamako, Mali.
Abdoulaye K KoneUniversity of Sciences, Techniques, and Technologies, Bamako, Bamako, Mali.
Karim TraoreUniversity of Sciences, Techniques, and Technologies, Bamako, Bamako, Mali.
Youssouf ToloUniversity of Sciences, Techniques, and Technologies, Bamako, Bamako, Mali.
Vladimir MishcherkinCenter for Vaccine Development and Global Health, University of Maryland School of Medicine, Baltimore, MD, USA.
Lorraine SoissonUnited States Agency for International Development, Washington, DC, USA.
Carter L DiggsUnited States Agency for International Development, Washington, DC, USA.
William C BlackwelderCenter for Vaccine Development and Global Health, University of Maryland School of Medicine, Baltimore, MD, USA.
Matthew B LaurensCenter for Vaccine Development and Global Health, University of Maryland School of Medicine, Baltimore, MD, USA.
Marcelo B SzteinCenter for Vaccine Development and Global Health, University of Maryland School of Medicine, Baltimore, MD, USA.
Ogobara K DoumboUniversity of Sciences, Techniques, and Technologies, Bamako, Bamako, Mali.
Christopher V PloweCenter for Vaccine Development and Global Health, University of Maryland School of Medicine, Baltimore, MD, USA.
Kirsten E LykeCenter for Vaccine Development and Global Health, University of Maryland School of Medicine, Baltimore, MD, USA.
Université des Sciences, des Techniques et des Technologies de Bamako · MLUniversity of Maryland, Baltimore · USUnited States Agency for International Development · USWalter Reed Army Institute of Research · US

Funding

Technology CoreU19AI110820 · NIAID · UNIVERSITY OF MARYLAND BALTIMORE · PI RASKO, DAVID A · 2014 to 2023
$36.5M
Clinical trial of trimethoprim-sulfamethoxazole or chloroquine in adults on ARTU01AI089342 · NIAID · UNIVERSITY OF MARYLAND BALTIMORE · PI LAUFER, MIRIAM K. · 2011 to 2017
$13.7M
Safety, Immunogenicity and Efficacy of VaccineU19AI065683 · NIAID · UNIVERSITY OF MARYLAND BALTIMORE · PI BLACKWELDER, WILLIAM C. · 2005 to 2009
$4.7M
MALARIA RESEARCH TRAINING IN MALID43TW001589 · FIC · UNIVERSITY OF MARYLAND BALTIMORE · PI PLOWE, CHRISTOPHER V. · 2000 to 2015
$2.8M
Immuno-epidemiological epitope mapping of a blood stage malaria vaccine antigenR01AI093635 · NIAID · UNIVERSITY OF MARYLAND BALTIMORE · PI PLOWE, CHRISTOPHER V. · 2012 to 2015
$2.3M
Immunologic Determinants of Schistosoma-mediated Resistance to Malaria in HumansR01AI067954 · NIAID · UNIVERSITY OF MARYLAND BALTIMORE · PI LYKE, KIRSTEN E · 2008 to 2011
$1.1M
Protein microarray antibody responses to P. falciparum in a human challenge modelK23AI125720 · NIAID · UNIVERSITY OF MARYLAND BALTIMORE · PI BERRY, ANDREA · 2017 to 2021
$915k
A Systems Biology Approach to Malaria ImmunityR01AI110852 · NIAID · HENRY M. JACKSON FDN FOR THE ADV MIL/MED · PI WILLIAMSON, KIM C · 2015 to 2015
$778k
Department of the Army W81XWH-15-R-0034FIC NIH HHS D43 TW001589FIC NIH HHS D43TW001589Joint Warfighter Medical Research Program W81XWH-JW14843National Institute of Allergy and Infectious Diseases R01AI067954National Institute of Allergy and Infectious Diseases R01AI110852National Institute of Allergy and Infectious Diseases U19AI065683National Institute of Allergy and Infectious Diseases U19AI110820National Institute of Allergy and Infectious Diseases (US) K23AI125720National Institute of Allergy and Infectious Diseases (US) R01AI093635NIAID NIH HHS HHSN272201000049INIAID NIH HHS K23 AI125720NIAID NIH HHS R01 AI067954NIAID NIH HHS R01 AI093635NIAID NIH HHS R01 AI110852NIAID NIH HHS U01 AI089342NIAID NIH HHS U19 AI065683NIAID NIH HHS U19 AI110820
6 · The paper itself

Abstract

backgroundA malaria vaccine based on Plasmodium falciparum apical membrane antigen 1 (AMA1) elicited strain specific efficacy in Malian children that waned in the second season after vaccination despite sustained AMA1 antibody titers. With the goal of identifying a humoral correlate of vaccine-induced protection, pre- and post-vaccination sera from children vaccinated with the AMA1 vaccine and from a control group that received a rabies vaccine were tested for AMA1-specific immunoglobulin G (IgG) subclasses (IgG1, IgG2, IgG3, and IgG4) and for antibody avidity.

methodsSamples from a previously completed Phase 2 AMA1 vaccine trial in children residing in Mali, West Africa were used to determine AMA1-specific IgG subclass antibody titers and avidity by ELISA. Cox proportional hazards models were used to assess correlation between IgG subclass antibody titers and risk of time to first or only clinical malaria episode and risk of multiple episodes. Asexual P. falciparum parasite density measured for each child as area under the curve were used to assess correlation between IgG subclass antibody titers and parasite burden.

resultsAMA1 vaccination did not elicit a change in antibody avidity; however, AMA1 vaccinees had a robust IgG subclass response that persisted over the malaria transmission season. AMA1-specific IgG subclass responses were not associated with decreased risk of subsequent clinical malaria. For the AMA1 vaccine group, IgG3 levels at study day 90 correlated with high parasite burden during days 90-240. In the control group, AMA1-specific IgG subclass rise and persistence over the malaria season was modest and correlated with age. In the control group, titers of several IgG subclasses at days 90 and 240 correlated with parasite burden over the first 90 study days, and IgG3 at day 240 correlated with parasite burden during days 90-240.

conclusionsNeither IgG subclass nor avidity was associated with the modest, strain-specific efficacy elicited by this blood stage malaria vaccine. Although a correlate of protection was not identified, correlations between subclass titers and age, and correlations between IgG subclass titers and parasite burden, defined by area under the curve parasitaemia levels, were observed, which expand knowledge about IgG subclass responses. IgG3, known to have the shortest half-life of the IgG subclasses, might be the most temporally relevant indicator of ongoing malaria exposure when examining antibody responses to AMA1.

Indexed as

Antibodies, ProtozoanAntibody AffinityAntigens, ProtozoanChildChild, PreschoolFemaleHumansImmunoglobulin GInfantMalaria VaccinesMaleMaliMembrane ProteinsPlasmodium falciparumProtozoan ProteinsAntibodies, ProtozoanAntigens, Protozoanapical membrane antigen I, PlasmodiumImmunoglobulin GMalaria VaccinesMembrane ProteinsProtozoan ProteinsAdjuvantArea under the curveAvidityImmunoglobulin G subclassMalaria vaccineNatural exposure

Identifiers

PMID30658710
PMCPMC6339315
OpenAlexW2910455764

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.